TY - JOUR T1 - New Aspects of Diabetes Research and Therapeutic Development JF - Pharmacological Reviews JO - Pharmacol Rev SP - 1001 LP - 1015 DO - 10.1124/pharmrev.120.000160 VL - 73 IS - 3 AU - Leslie S. Satin AU - Scott A. Soleimanpour AU - Emily M. Walker A2 - Isom, Lori Y1 - 2021/07/01 UR - http://pharmrev.aspetjournals.org/content/73/3/1001.abstract N2 - Both type 1 and type 2 diabetes mellitus are advancing at exponential rates, placing significant burdens on health care networks worldwide. Although traditional pharmacologic therapies such as insulin and oral antidiabetic stalwarts like metformin and the sulfonylureas continue to be used, newer drugs are now on the market targeting novel blood glucose–lowering pathways. Furthermore, exciting new developments in the understanding of beta cell and islet biology are driving the potential for treatments targeting incretin action, islet transplantation with new methods for immunologic protection, and the generation of functional beta cells from stem cells. Here we discuss the mechanistic details underlying past, present, and future diabetes therapies and evaluate their potential to treat and possibly reverse type 1 and 2 diabetes in humans.Significance Statement Diabetes mellitus has reached epidemic proportions in the developed and developing world alike. As the last several years have seen many new developments in the field, a new and up to date review of these advances and their careful evaluation will help both clinical and research diabetologists to better understand where the field is currently heading. ER -